Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity and Safety of GlaxoSmithKline Biologicals' (Pre-) Pandemic Influenza Vaccine Prepandrix™ in Korean Subjects Aged 18 to 60 Years Old

NCT01730378 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01730378
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01730378 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity and Safety of GlaxoSmithKline Biologicals' (Pre-) Pandemic Influenza Vaccine Prepandrix™ in Korean Subjects Aged 18 to 60 Years Old
Lead sponsor
GlaxoSmithKline
Phase
Phase 4
Overall status
Completed
Start date
December 5, 2012
Completion date
December 17, 2013
Enrollment
131 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

influenza